Andere Sprachen Kinnate Biopharma Inc.

Aktien

A2QHVT

US49705R1059

KNTE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 02.04.2024			% 5 Tage	% 1. Jan.
2,65 ^USD	-0,38 %		0,00 %	+11,81 %

03.04.	Kinnate Biopharma Inc. kündigt Rücktritt des Vorstands an	CI
03.04.	Die XOMA Corporation (NasdaqGM:XOMA) hat die Übernahme von Kinnate Biopharma Inc. (NasdaqGS:KNTE) abgeschlossen.	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Kinnate Biopharma Inc. Announces Board Resignations	03.04.
XOMA Corporation Announces Closing of Tender Offer	03.04.
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	03.04.
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	03.04.
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from S&P TMI Index	03.04.
North American Morning Briefing : Stocks Seen -2-	02.04.
Kinnate Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
North American Morning Briefing : Markets Steady -2-	26.03.
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	19.03.
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE	13.03.
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories	04.03.
Kinnate Biopharma Sells Cancer Treatment Assets to Pierre Fabre Laboratories	01.03.
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories	01.03.
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories	01.03.
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE	19.02.
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	19.02.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.	16.02.
Sector Update: Health Care Stocks Advance Friday Afternoon	16.02.
XOMA Agrees to Acquire Kinnate Biopharma	16.02.
KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders	16.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Kinnate Biopharma Inc.

Aktien

A2QHVT

US49705R1059

KNTE

Andere Sprachen

Filter